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Abstract: OBJECTIVES Extracorporeal membrane oxygenation (ECMO) has become an essential life-
saving tool. Being resource-intensive, judicious use and optimising the outcomes of this precious resource
is important. This retrospective, explanatory, observational study aimed to quantify associations between
factors and outcome after pulmonary ECMO in children. METHODS This study included 39 consecutive
ECMO runs in 38 children performed for pulmonary indications at our hospital from 2008 to 2018.
Indications included acute respiratory distress syndrome, infection, drowning, meconium aspiration and
pulmonary hypertension, among others. Depending on the need for haemodynamic support, 21 patients
(53.8%) received veno-venous ECMO, while 18 (46.2%) received veno-arterial ECMO. We sought to
compare the 11 non-survivors with the 27 survivors with respect to time-independent and time-dependent
variables. Logistic regression models and Cox proportional hazards models were used. Threshold analysis
was done using the ldquo;minimum p-value approachrdquo;. RESULTS 27/39 (69%) ECMO runs could
be weaned; 27/38 (71%) patients were discharged. 20/27 (74%) survivors had unremarkable neurological
status, six (22%) had mild findings (convulsions, muscular hypotony, neuropathy) and one (4%) had a
hemi-syndrome at discharge. Univariate analyses showed a hazard ratio (HR) of 0.48 for log(pH) (95%
confidence interval [CI] 0.22 to 1.02, p = 0.055) and an HR of 4.48 for log(lactate) (95% CI 1.92 to 10.48,
p = 0.0005). Multivariate models showed an HR of 0.99 for log(pH) (95% CI 0.43 to 2.26, p = 0.98) and
an HR of 4.44 for log(lactate) (95% CI 1.65 to 11.95, p = 0.003). Threshold analysis showed lactate gt;4.1
to be associated with mortality, with an HR of 32.7 (95% CI 4.8 to 221.7, p = 0.0002). This threshold
should, however, be interpreted very cautiously. Evidence of an association between serum lactate at
24 hours and mortality was found (difference between survivors and non-survivors: minus;2.78, 95% CI
minus;5.36 to minus;0.20, p = 0.037). CONCLUSIONS The results of ECMO for pulmonary indications
are very good. Serum lactate may be an early prognostic indicator.
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Summary
OBJECTIVES: Extracorporeal membrane oxygenation
(ECMO) has become an essential life-saving tool. Being
resource-intensive, judicious use and optimising the out-
comes of this precious resource is important. This retro-
spective, explanatory, observational study aimed to quan-
tify associations between factors and outcome after
pulmonary ECMO in children.
METHODS: This study included 39 consecutive ECMO
runs in 38 children performed for pulmonary indications at
our hospital from 2008 to 2018. Indications included acute
respiratory distress syndrome, infection, drowning, meco-
nium aspiration and pulmonary hypertension, among oth-
ers. Depending on the need for haemodynamic support,
21 patients (53.8%) received veno-venous ECMO, while
18 (46.2%) received veno-arterial ECMO. We sought to
compare the 11 non-survivors with the 27 survivors with
respect to time-independent and time-dependent vari-
ables. Logistic regression models and Cox proportional
hazards models were used. Threshold analysis was done
using the “minimum p-value approach”.
RESULTS: 27/39 (69%) ECMO runs could be weaned;
27/38 (71%) patients were discharged. 20/27 (74%) sur-
vivors had unremarkable neurological status, six (22%)
had mild findings (convulsions, muscular hypotony, neu-
ropathy) and one (4%) had a hemi-syndrome at discharge.
Univariate analyses showed a hazard ratio (HR) of 0.48
for log(pH) (95% confidence interval [CI] 0.22 to 1.02, p =
0.055) and an HR of 4.48 for log(lactate) (95% CI 1.92 to
10.48, p = 0.0005). Multivariate models showed an HR of
0.99 for log(pH) (95% CI 0.43 to 2.26, p = 0.98) and an HR
of 4.44 for log(lactate) (95% CI 1.65 to 11.95, p = 0.003).
Threshold analysis showed lactate >4.1 to be associated
with mortality, with an HR of 32.7 (95% CI 4.8 to 221.7,
p = 0.0002). This threshold should, however, be interpret-
ed very cautiously. Evidence of an association between
serum lactate at 24 hours and mortality was found (differ-
ence between survivors and non-survivors: −2.78, 95% CI
−5.36 to −0.20, p = 0.037).
CONCLUSIONS: The results of ECMO for pulmonary in-
dications are very good. Serum lactate may be an early
prognostic indicator.
Keywords: ECMO, paediatric, hypoxia, outcomes, tem-
porary circulatory support
Introduction
Extracorporeal membrane oxygenation (ECMO) is a life-
saving tool and a substantial part of every mechanical cir-
culatory support programme. The use of ECMO has grown
constantly and substantially [1, 2], with an increasing num-
ber of centres and increased applications for its use. Indi-
cations include pulmonary and/or cardiac decompensation,
elective post-cardiotomy situations and emergency extra-
corporeal cardiopulmonary resuscitation (ECPR) scenar-
ios. ECMO is a highly invasive therapy with substantial
risks of haemorrhagic and thromboembolic complications.
The morbidity and mortality associated with ECMO are
due to both the native disease processes that lead to ECMO
and the complications of ECMO itself. ECMO therapy in-
volves enormous resources, such as a specialised team of
trained therapists, necessary space in the intensive care
unit, blood products, and the high costs of the machines
and disposables. As an efficient life-saving tool, it has be-
come an essential round-the-clock part of every CPR drill.
Increased ECMO demand may lead to strain on intensive
care resources, occasionally necessitating delays in treat-
ment and the diversion/airlifting of critical patients to dis-
tant tertiary centres. Under these circumstances, develop-
ing objective parameters which help decision making in
order to optimise ECMO availability is imperative [3].
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mine the use and allocation of ECMO is an ambitious tar-
get. However, such studies could stimulate research into
thresholds which could guide physicians and care takers in
determining prognosis. Serum lactate is one such common-
ly used marker of tissue perfusion. Elevated lactate levels
and the dynamics of lactate washout could provide insights
into the recovery of critical patients [3]. Prior studies in
neonatal and paediatric patients undergoing cardiac ECMO
have shown that elevated lactate (>24–72 hours post-can-
nulation) is associated with increased mortality [4]. This
study evaluated the dynamics of serum lactate and serum
pH over time and assessed their possible associations with
outcome.
Patients and methods
Permission from the Cantonal ethic commission, Zurich
for the study of ECMO in children was sought and award-
ed (No.2019-00184, dated 19 march 2019).
Study population
All paediatric patients (0–18 years) who underwent ECMO
for pulmonary indications at the University Children’s
Hospital Zurich from 2008 to 2018 formed the subject co-
hort of this exploratory study. This collection included 39
ECMO runs performed in 38 patients. One patient was sub-
jected to two ECMO runs; these were considered as two
separate ECMO runs.
Data collection
The time-independent variables collected included the pa-
tient’s age, weight, pre-ECMO oxygenation index (OI), in-
dication for ECMO, type of ECMO (veno-venous [VV] or
veno-arterial [VA]), time from the first symptom to ECMO
(in days) and duration of ECMO (in days). The time-de-
pendent variables were pH and lactate, which were mea-
sured at the beginning of and several times during the EC-
MO therapy.
End points
The primary outcome was the survival of the patient (sur-
vivor/non-survivor) at hospital discharge.
Statistical methods
Statistical analysis was performed using the software R
(version 3.5.2). Continuous variables were summarised as
medians (interquartile range [IQR]), categorical variables
were summarised as frequencies (%). The explanatory p-
values in table 1 below were computed using the Kruskal-
Wallis rank sum test for the continuous (non-normal) vari-
ables and Pearson’s chi-square test (with continuity
correction) for the categorical variables. Time-independent
variables were analysed using univariate and multivariate
Firth's logistic regression analyses. The time-independent
variables with distributions skewed to the right (time from
the first symptom to ECMO and duration of ECMO) were
log-transformed to reduce the influence of extreme values.
Time-dependent variables were analysed using univariate
and multivariate time-dependent Cox proportional hazards
regression models. Since lactate had a skewed distribution
and pH had a very small standard deviation, we log-trans-
formed these variables to reduce the influence of extreme
values and scaled them to avoid unreasonable estimates
and standard errors. The proportional hazards assumption
was checked by inspecting the Schoenfeld residuals and a
test for proportional hazards assumption by Grambsch and
Therneau [5]. The jackknife method was used to examine
the influence of individual observations on the Cox model
estimates. A threshold analysis for lactate was performed
to find a cut-off value with which to classify patients as at
low or high risk of death. This was done using the 'min-
imum p-value approach' [6], i.e., we fitted a Cox regres-
sion model with Firth’s penalised likelihood. The p-values
were corrected for multiple testing using the method de-
scribed by Schumacher et al. [6]. The estimated hazard ra-
tio (HR) and its confidence interval (CI) were corrected
with a heuristic shrinkage factor [7]. As a sensitivity analy-
sis for the heuristic shrinkage factor, we used the unadjust-
ed and adjusted p-values to estimate a shrinkage factor for
correcting the HR and its CI. Missing values in the regres-
sion analyses were treated with 'complete case analysis'.
No adjustment for multiple testing was done, except for the
threshold analysis.
Results
Analysis of time-independent variables
The baseline characteristics of the patients stratified by the
outcome of interest (survival) are summarised in table 1.
Of the 39 ECMO runs in 38 patients, 27 (69%) could be
weaned, while 12 runs (31%) in 11 patients could not be
weaned. The latter included one patient who had two EC-
MO runs. Age, weight and duration of ECMO showed sim-
ilar medians and overlapping IQRs and did not differ be-
tween survivors and non-survivors. Figure 1 depicts box
and bar plots of various variables stratified by outcome.
There were five (12.8%) missing values for the variable
“time (1st symptom to ECMO)”, 12 (30.8%) for OI, 14
(35.9%) for height and 14 (35.9%) for hospital stay.
Analysis of time-dependent serum pH and lactate
Longitudinal measurements of serum pH and lactate were
analysed. The median number of blood measurements for
each patient was 96 (IQR 58.0 to 128.2) and the median
time between any two measurements was two hours (IQR
0.7 to 2.6). One patient had a gap of more than 12 days
between two blood measurements. This gap occurred be-
cause the patient had to be airlifted to another tertiary cen-
tre after the ECMO implantation because of a lack of in-
tensive care bed capacity. This patient returned after 12
days. We removed the 12-day interval of that patient from
the survival analysis to avoid assuming constant measure-
ments for such a long period. Figure 2 depicts the consec-
utive pH and lactate values of the patients. Survivors are
represented by blue dotted lines, non-survivors by red dot-
ted lines. The lactate values ranged from 0.1 to 22 and the
pH values from 6.4 to 7.9.
Univariate and multivariate analyses: factors associat-
ed with survival
Time-independent variables
The following time-independent variables were included
in the univariate analyses to investigate factors associated
with survival at discharge:
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1. Weight: odds ratio 1.01 (95% CI 0.93 to 1.1, p = 0.78)
2. Oxygenation index: odds ratio 1.00 (95% CI 0.97 to
1.03, p = 1.00)
3. Log(time from the first symptom to ECMO): odds ra-
tio 0.72 (95% CI 0.41 to 1.26, p = 0.25)
4. Type of ECMO (reference category VV): odds ratio
0.29 (95% CI 0.07 to 1.23, p = 0.09)
5. Log(duration of ECMO): odds ratio 1.06 (95% CI 0.46
to 2.42, p = 0.90)
6. Indication for ECMO (acute respiratory distress syn-
drome [ARDS] being the reference category):
Pneumonia/respiratory syncytial virus/viral infection:
odds ratio 25.68 (95% CI 0 to 357765.46, p = 0.50)
Drowning: odds ratio 0.73 (95% CI 0.02 to 28.93, p =
0.87)
Meconium aspiration: odds ratio 1.15 (95% CI 0.03 to
37.91, p = 0.94)
Pulmonary hypertension: odds ratio 1.04 (95% CI 0.07
to 16.23, p = 0.98)
Other: odds ratio 9.36 (95% CI 0.01 to 14886.47, p =
0.55)
A multivariate model with time from the first symptom to
ECMO and duration of ECMO as explanatory variables
found no evidence of an association of these variables with
survival (time from the first symptom to ECMO: odds ratio
0.65, 95% CI 0.35 to 1.22, p = 0.18; duration of ECMO:
odds ratio 1.71, 95% CI 0.67 to 4.36, p = 0.26).
Time-dependent variables
Longitudinal measurements of serum pH and lactate were
included in time-dependent Cox proportional hazards
models. The results are shown in figure 3. While the uni-
variate analysis showed weak evidence of an association
between log(pH) and survival (HR 0.48, 95% CI 0.22 to
1.02, p = 0.055), this effect vanished when log(lactate) was
also included in the model (HR 0.99, 95% CI 0.43 to 2.26,
p = 0.98). The univariate model provided very strong ev-
idence of an effect of log(lactate) on survival (HR 4.48,
95% CI 1.92 to 10.48, p = 0.0005). The multivariate model
provided strong evidence of an effect of log(lactate) (HR
4.44 (95% CI 1.65 to 11.95, p = 0.003) when log(pH) was
also included. The estimated concordance index was 0.646
(standard error [SE] 0.113) for the univariate model with
log(pH), 0.817 (SE 0.075) for the univariate model with
log(lactate) and 0.825 (SE 0.07) for the multivariate mod-
el.
Table 1: Descriptive analysis of the variables.
Overall Non-Survivors Survivors p-value




































Respiratory indication, n (%) 0.219
– ARDS 18 (46.2) 8 (66.7) 10 (37.0)
– Pneumonia / respiratory syncytial virus / viral infection 7 (17.9) 0 (0.0) 7 (25.9)
– Drowning 2 (5.1) 1 (8.3) 1 (3.7)
– Meconium aspiration 3 (7.7) 1 (8.3) 2 (7.4)
– Pulmonary hypertension 5 (12.8) 2 (16.7) 3 (11.1)
– Others 4 (10.3) 0 (0.0) 4 (14.8)
Type of ECMO, n (%) 0.172
– VV 21 (53.8) 4 (33.3) 17 (63.0)
– VA 18 (46.2) 8 (66.7) 10 (37.0)










































ARDS = acute respiratory distress syndrome; ECMO = extracorporeal membrane oxygenation; VA = veno-arterial; VV = veno-venous All continuous variables are summarised as
medians (interquartile range) and all categorical variables are summarised as frequencies (%). The exploratory p-values were computed using the Kruskal-Wallis rank sum test for
the continuous (non-normal) variables and Pearson’s chi-square test (with continuity correction) for the categorical variables. * Lactate >2 mmol/l and pH <7.34 were considered
abnormal.
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Figure 1: Distribution of the time-independent predictors stratified
by outcome.
Figure 2: Lactate and pH curves during intensive therapy (sur-
vivors / non-survivors). Lactate >2 mmol/l and pH <7.34 were con-
sidered abnormal.
Evolution of lactate (during first 48 hours of intensive
therapy)
Table 2 depicts the means of the most recent lactate values
at different times of survivors and of non-survivors, the
differences between these means, the 95% CIs of those
differences and the corresponding p-values. The p-values
were computed using Welch two sample t-tests. Serum lac-
tate at 24 hours was lower in survivors than in non-sur-
vivors (difference 2.78, 95% CI −5.36 to −0.20, p = 0.037).
Serum lactate during the first 24 hours of intensive therapy
in survivors and non-survivors is shown in figure 4.
Threshold analysis for lactate
The minimal p-value was reached at a cut-off value of 4.1
for lactate. Having a lactate value >4.1 instead of ≤4.1 in-
creased the risk of death by a factor of 32.7 (95% CI 4.8 to
221.7, p = 0.0002). The unadjusted HR was 43.0 (95% CI
8.23 to 427.7, p = 0.000007). The sensitivity analysis pro-
vided an adjusted HR of 8.6 (95% CI 2.6 to 70.7).
Figure 3: Confidence intervals of estimated hazard ratios of pH
and lactate from univariate and multivariate models.
Figure 4: Serum lactate during the first 24 hours of intensive ther-
apy in non-survivors (above) and survivors (below). The black dots
and the line correspond to the means and 95% CIs of the first lac-
tate values, at time 0, and to the latest lactate values before 6, 12
and 24 hours after the start of ECMO. Of note, if a line starts, for
example, below 4.1 and goes over the threshold of 4.1, it is still
displayed as blue, since the measurement was considered con-
stant from this time point onwards until the next measurement.
Table 2: Evolution of serum lactate during the first 48 hours of intensive therapy.
Last lactate Mean, survivors Mean,
non-survivors
Difference Confidence interval p-Value
At 6 hours 3.55 4.50 −0.95 −3.53 to 1.63 0.448
At 12 hours 2.50 5.02 −2.52 −5.07 to 0.04 0.053
At 24 hours 1.80 4.58 −2.78 −5.36 to −0.20 0.037
At 48 hours 1.45 3.68 −2.23 −4.78 to 0.33 0.081
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Discussion
ECMO therapy has come a long way since it was first de-
veloped by Gibbon and Lillehei in the 1950s [8]. Having
initially been used for respiratory support in adults, it has
expanded and established itself as having a critical life-
saving role in all age groups; for cardiac, pulmonary and
metabolic recovery; and in elective, urgent and ECPR sce-
narios [9, 10]. Due to improving results and greater avail-
ability of ECMO therapy, the demand for ECMO has been
steadily increasing [11].
The primary goal of this therapy is to salvage all patients.
Survival to discharge in the presented series is 71%. This is
comparable to a survival of 70.6% out of a total of 36,705
respiratory ECMO runs in children reported in the Extra-
corporeal Life Support Organization (ELSO) registry [1].
The question is whether we can analyse other variables and
find modifiable factors which may help salvage some of
the remaining 30% of patients.
Indications for pulmonary ECMO
The indications for ECMO involved six diagnostic cate-
gories. The small cohort size distributed across six cate-
gories made this study underpowered to demonstrate dif-
ferences in outcome. Despite this, it appears that ARDS
and pulmonary hypertension were more frequent in non-
survivors. Larger study cohorts would be necessary to de-
cipher the associations of these variables with survival.
Time from first symptom to ECMO
Median time from the first symptom to ECMO was almost
double in non-survivors compared to in survivors. Al-
though the study failed to provide evidence for this as-
sociation, this finding may stimulate debate and further
studies to deduce whether early ECMO, before the onset
of multi-organ dysfunction or irreversible damage to lung
parenchyma, could improve survival.
Oxygenation index
OI was greater in non-survivors than in survivors (38.7,
IQR 28.9 to 47.3, versus 22.9, IQR 14.3 to 44.0), without
evidence that it differed significantly between the two
groups. Whether the lack of evidence is a consequence of
the study being underpowered or otherwise, this may point
to a beneficial effect of implementing ECMO early, when
the OI is still low.
Veno-venous versus veno-arterial ECMO
Univariate analysis of our cohort showed greater odds of
survival with VV ECMO (OR 0.29, 95% CI 0.07 to 1.23,
p = 0.09). While this may just reflect a selection bias (VA
ECMO is necessary in sicker patients), a discussion about
the pathophysiology is warranted. VV ECMO is theoret-
ically meant to provide only oxygenation and ventilatory
support, while depending on autogenous cardiac function
for haemodynamic stability. However, patients with lung
pathologies, who are subjected to ECMO after a lengthy
high-pressure ventilatory therapy, invariably suffer from
inadequate left heart preload, thus resulting in a need for
high ionotropic support. We have observed that in many
cases subjected to VV ECMO, perfusion of oxygenated
blood into the lungs and lung rest ventilation lead to better
pass-through across the lungs and immediate decongestion
of the central venous system. This results in rapid wean-
ing of ionotropic support. In addition, VV ECMO reduces
the risk of systemic embolisation and is often performed
through a less invasive double-lumen jugular venous can-
nulation.
In our sample, non-survivors were more likely to have a
diagnosis of ARDS, a longer time from the first symptom
to ECMO (median 8 days in non-survivors versus 4 days
in survivors) and to have had prolonged ventilator therapy
resulting in a high OI (median 39 in non-survivors versus
23 in survivors), suggesting certain actionable factors [12].
It may be argued that earlier ECMO support for fulmi-
nating infectious-inflammatory pathologies could prevent
irreversible lung destruction and lead to better outcomes.
Early ECMO may even allow many of these patients to
be treated with VV ECMO, with relatively less morbidity.
ELSO data tend to support this hypothesis, with time to
ECMO >7–14 days, (OR 0.32, p <0.001), presence of
cardiac arrest (OR 0.56, p = 0.001), pH per 0.1 unit in-
crease (OR 1.15, p <0.001), higher OI per 10 unit increase
(OR 0.95, p = 0.002) and diagnosis of sepsis being asso-
ciated with unfavourable outcomes [13]. Bayrakci et al.
[12] showed that an OI of 33.2 is a suitable cut-off value
for ECMO initiation, correlating with high sensitivity and
specificity. They further concluded that an OI >40 is asso-
ciated with a high risk of chronic lung disease when not
supported by ECMO.
Indicators of bad prognosis
Being a highly resource intensive, high-end therapy, EC-
MO puts a strain on resources at the tertiary medical in-
stitutions where these patients are treated. This may occa-
sionally lead to the cancellation of planned operations, the
transport and airlifting of critically ill patients to other cen-
tres, etc. Our hospital practices a three tier (surgeon, as-
sistant, cardiac perfusionist) ECMO alarm system for any
reanimation lasting more than five minutes, resulting in
approximately 30 ECMO alarms a year. We have three
ECMO systems (Levitronix®) at the University Children’s
Hospital Zurich, catering to an area with a population of
about 4 million. The secondary goal of such high-end ther-
apy is to discern markers of prognosis. Objective, verifi-
able criteria, similar to those which exist for brain death,
are needed when logistics demand that this precious ther-
apy is allocated to those patients most likely to benefit
from it. The present coronavirus (COVID-19) pandemic
has raised the possibility that even the availability of me-
chanical ventilators may fall short of the demand, thus vin-
dicating our endeavour. Despite optimal salvage and trans-
port, there may still be patients who are attended too late,
when irreversible organ damage has already set in, for ex-
ample after drowning. Clinical and lab markers suggestive
of the point of no return need to be developed so as to en-
able objective, informed decision making. While our small
dataset could not demonstrate a cut-off value of low pH
which implies a bad prognosis, ELSO data have shown pH
to be a risk factor. Brunner et al [14], studying their ECPR
results, showed that the median lowest pH of survivors be-
fore ECMO was 7.08 (IQR from 7.1 to 7.3), while that of
non-survivors was 6.7 (IQR from 6.6 to 6.9).
Our study found increased serum lactate to be associated
with higher mortality (fig. 3). However, potential con-
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founding factors cannot be excluded. A threshold value of
>4.1 is associated with a 33-fold (95% CI 4.8 to 221.7, p
= 0.0002) greater risk of death compared to patients with
serum lactate ≤4.1. However, this result should be inter-
preted very carefully. The estimated HR seems extreme-
ly high and differs from the sensitivity analysis estimate
by quite a lot. This could indicate that the corrected es-
timate is still exaggerated. A known disadvantage of the
“minimum p-value approach” is that one cannot know by
exactly how much the estimates are overestimated. There
are various correction techniques for shrinking the esti-
mate, but these cannot be checked without an independent
dataset for validation. In general, this method is known to
be very data-dependent, leading to different cut-off points
[15]. The lactate threshold of 4.1 should therefore be re-
garded as a guide for future studies which could then in-
vestigate it without the problem of multiple testing. Yang
et al. [16] showed that lactate >5 mmol/l was the most sig-
nificant indicator of 30-day mortality. It is notable that in
a post-cardiotomy scenario, Siegel et al. [17] reported lac-
tate >4.5 to be highly predictive of mortality. Buijs et al.
[18] [19] have suggested that in addition to static lactate
values, dynamic values, i.e., trends over time, may be bet-
ter predictors of survival in paediatric age groups, but not
in neonates. These studies suggest that lactate is a poten-
tial marker whose dynamics for different age groups, dif-
ferent indications and different clinical situations should
be prospectively studied in order to create evidence-based
guidelines.
Limitations
Our study has the limitations inherent to a retrospective
study. The small number of patients in the cohort, the het-
erogeneity of aetiology and the variability of other fac-
tors, in the context of the number of events that occurred,
make this study considerably underpowered. Moreover,
the small number of events limited the possibility of ad-
justing the analysis for potential confounders. Various fac-
tors such as the operator, era, ECMO flows, unexpected
detrimental events, etc., which may have influenced the
outcomes, were not studied. A selection bias regarding
VV/VA is plausible, and confounding effects cannot be
ruled out. These factors should form the basis of future
studies.
Conclusion
Our study has demonstrated that serum lactate level might
provide guidance on prognosis in ECMO therapy per-
formed for pulmonary indications. However, static and dy-
namic lactate levels, lactate clearance over time, and the
influence of age on serum lactate, among others aspects,
need to be further studied, with detailed data collection and
analysis, in order to provide conclusive guidelines.
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